Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia

Annals of Oncology

Volumn 9, Issue 7, 1998, Pages 721-726

  Betticher, D C ^a,i   Ratschiller, D ^a   Hsu Schmitz, S F ^b   Von Rohr, A ^c   Hess, U ^d   Zulian, G ^e   Wernli, M ^f   Tichelli, A ^g   Tobler, A ^h   Fey, M F ^a   Cerny, T ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b SIAK Coordinating Center   (Switzerland)

^c Division of Oncology   (Switzerland)

^d Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^e Division of Oncology   (Switzerland)

^f Kantonsspital Aarau   (Switzerland)

^g Division of Haematology   (Switzerland)

^h Division of Haematology   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

2 chlorodeoxyadenosine; Chronic lymphocytic leukaemia; Cladribine; Infection; Myelotoxicity; Remission duration

Indexed keywords

CLADRIBINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 7344254620     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008273131598     Document Type: Article

References (24)

1. Astrow AB. Fludarabine in chronic leukemia. Lancet 1996; 347: 1420-1.
2. Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Semin Hematol 1996; 33(1 Suppl 1):28-33.
3. Keating MJ. Clinical trials of the purine analogs in chronic lymphocytic leukemia. In Cheson BD, Keating MJ, Plunkett W (eds): Nucleoside Analogs in Cancer Therapy. New York Basel Hong Kong: Marcel Dekker 1997; 12: 201-26.
4. Bergmann L. Present status of purine analogs in the therapy of chronic lymphocytic leukemias. Leukemia 1997; 11 (Suppl 2): S29-34.
5. Pott C, Hiddemann W. Purine analogs in the treatment of chronic lymphocytic leukemia. Leukemia 1997; 11 (Suppl 2): S25-8.
6. Saven A, Carrera CJ, Carson DA et al. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymph 1991; Suppl: 133-8.
7. Piro LD, Carrera CJ, Beutler E et al. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069-73.
8. Juliusson G, Liliemark J. Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 1996; 7: 373-9.
9. Brugiatelli M, Holowiecka B, Dmoszynska A et al. 2-chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. Ann Haematol 1996; 73: 79-84.
10. Tallman MS, Hakimian D, Zanzig C et al. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-8.
11. Delannoy A, Ferrant A, Martiat P et al. 2-chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia. Nouv Rev Fr Hematol 1994; 36: 311-5.
12. Betticher DC, Fey MF, Von Rohr A et al. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias. Ann Oncol 1994; 5: 57-64.
13. Robak T, Blasinka-Morawiec M, Krykowski E et al. Intermittant two-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymph 1996; 22: 509-14.
14. Juliusson G, Christiansen I, Hansen MM et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-6.
15. Delannoy A, Martiat P, Gala JL et al. 2-chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 1995; 9: 1130-5.
16. Betticher DC, Zucca E, Von Rohr A et al. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 793-9.
17. Mitterbauer M, Hilgenfeld E, Wilfing A et al. Is there a place for 2-CDA in the treatment of B-CLL? Leukemia 1997; 11 (Suppl 2): S35-7.
18. Sonderegger TA, Betticher DC, Egger T, et al. 2-chlorodeoxyadenosine (2-CDA), pharmacokinetic comparison of continuous intravenous (i.v.) and subcutaneous bolus (s.c.) application. Ann Oncol 1996; 7 (Suppl 3): 186 (Abstr 693).
19. Kazimierczuk Z, Cottam HB, Revankar GR et al. Synthesis of 2′-deoxytubercidin, 2′-deoxyadenosine. and related 2′-deoxynucleosides via a novel direct stereospecific sodium salt glycosylation procedure. J Am Chem Soc 1984; 106: 6379-82.
20. Cheson BD, Bennett JM, Rai KR et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored working group. Am J Hematol 1988; 29: 152 -63.
21. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
22. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48.
23. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906-11.
24. Van den Neste E, Delannoy A, Vandercam B et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235-40.